Overall, our data show that prevalence of anti‐SARS‐CoV‐2 IgM and/or IgG positivity in patients with CML was comparable to the general population in the same period both at national and regional levels, and reassure about the safety of continuing TKI treatment in patients with CML during the ongoing SARS‐CoV‐2 pandemic. The gene discussed is CD40LG; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.